Finn RS, Martin M, Rugo HS, Jones S, Im S‑A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.

Article  CAS  PubMed  Google Scholar 

Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–19.

Article  CAS  PubMed  Google Scholar 

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap Y‑S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–48.

Article  CAS  PubMed  Google Scholar 

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S‑A, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.

Article  CAS  PubMed  Google Scholar 

Johnston S, Martin M, Di Leo A, Im S‑A, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer. 2019;5:5.

Article  PubMed Central  PubMed  Google Scholar 

Slamon DJ, Neven P, Chia S, Fasching PA, de Laurentiis M, Im S‑A, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2‑negative advanced breast cancer: MONALEESA‑3. J Clin Oncol. 2018;36:2465–72.

Article  CAS  PubMed  Google Scholar 

Sonke GS, Van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). JCO. 2023;41:LBA1000–LBA1000.

Article  Google Scholar 

van Ommen-Nijhof A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, van der Noort V, Jager A, et al. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer—the SONIA study: study protocol for a randomized controlled trial. BMC Cancer. 2018;18:1146.

Article  PubMed Central  PubMed  Google Scholar 

Thill M, Kolberg-Liedtke C, Albert U‑S, Banys-Paluchowski M, Bauerfeind I, Blohmer J‑U, et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2023. Breast Care. 2023;18:306–15.

Article  PubMed Central  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA‑2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2019;30:1842.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Würstlein R, Kolberg H‑C, Hartkopf AD, Fehm TN, Welslau M, Schütz F, et al. Update breast cancer 2024 part 1—expert opinion on advanced breast cancer. Geburtshilfe Frauenheilkd. 2024;84:529–40.

Article  PubMed Central  PubMed  Google Scholar 

Al-Qasem AJ, Alves CL, Ehmsen S, Tuttolomondo M, Terp MG, Johansen LE, et al. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. NPJ Precis Oncol. 2022;6:68.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Lee JS, Hackbart H, Cui X, Yuan Y. CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer: translational research, clinical trials, and future directions. Int J Mol Sci. 2023;24:11791.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756.

Article  PubMed Central  PubMed  Google Scholar 

Gampenrieder S, Rinnerthaler G, Pichler A, Herz W, Petzer A, Dormann C, et al. Abstract PO1-05-13: drop-out rates from line to line of treatment in metastatic breast cancer (MBC): results from the austrian AGMT_MBC-registry. Cancer Res. 2024;84.

Perakis S, Speicher MR. Emerging concepts in liquid biopsies. BMC Med. 2017;15:75.

Article  PubMed Central  PubMed  Google Scholar 

Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, et al. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 2014;34:1071–7.

CAS  PubMed  Google Scholar 

Kim C, Lee J, Lee W, Kim A. Changes in intrinsic subtype of breast cancer during tumor progression in the same patient. Int J Clin Exp Pathol. 2015;8:15184–90.

PubMed Central  PubMed  Google Scholar 

Sant M, Bernat-Peguera A, Felip E, Margelí M. Role of ctDNA in breast cancer. Cancers. 2022;14:310.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the breast international group (BIG) molecular screening initiative. Cancer Discov. 2021;11:2796–811.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Kotecha R, Tonse R, Rubens M, McDermott MW, Odia Y, Appel H, et al. Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. Neurooncol Adv. 2021;3.

Priedigkeit N, Hartmaier RJ, Chen Y, Vareslija D, Basudan A, Watters RJ, et al. Intrinsic subtype switching and acquired ERBB2 / HER2 amplifications and mutations in breast cancer brain metastases. JAMA Oncol. 2017;3:666.

Article  PubMed Central  PubMed  Google Scholar 

Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol. 2020;22:1173–81.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Klebe M, Fremd C, Kriegsmann M, Kriegsmann K, Albrecht T, Thewes V, et al. Frequent molecular subtype switching and gene expression alterations in lung and pleural metastasis from luminal A‑type breast cancer. JCO Precis Oncol. 2020; 848–59.

Russo M, Bardelli A. Lesion-directed therapies and monitoring tumor evolution using liquid biopsies. Cold Spring Harb Perspect Med. 2017;7:a29587.

Article  PubMed Central  PubMed  Google Scholar 

Pascual J, Attard G, Bidard F‑C, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group. Ann Oncol. 2022;33:750–68.

Article  CAS  PubMed  Google Scholar 

Jørgensen CLT, Larsson A‑M, Forsare C, Aaltonen K, Jansson S, Bradshaw R, et al. PAM50 intrinsic subtype profiles in primary and metastatic breast cancer show a significant shift toward more aggressive subtypes with prognostic implications. Cancers. 2021;13:1592.

Article  PubMed Central  PubMed  Google Scholar 

Caballero C, Irrthum A, Goulioti T, Cameron D, Norton L, Piccart M. International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01). Npj Breast Cancer. 2023;9:42.

Article  PubMed Central  PubMed  Google Scholar 

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria J‑C, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13:e1002201.

Article  PubMed Central  PubMed  Google Scholar 

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427–438.e6.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine t